Management of salivary gland malignancies: Current and developing therapies

Oncology Reviews

Volumn 2, Issue 2, 2008, Pages 86-94

  Agulnik, Mark ^a   McGann, Camille F ^a   Mittal, Bharat B ^a   Gordon, Sara C ^b,c   Epstein, Joel B ^d  

^a NORTHWESTERN UNIVERSITY   (United States)

^b Division of Restorative and Prosthetic Dentistry   (United States)

^c UNIVERSITY OF ILLINOIS   (United States)

^d UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

Chemotherapy; Radiation therapy; Salivary gland neoplasm

Indexed keywords

EID: 84873578417     PISSN: 19705557     EISSN: 19705565     Source Type: Journal    
DOI: 10.1007/s12156-008-0062-4     Document Type: Review

References (88)

1. Speight PM and Barrett AW(2002) Salivary gland tumours. Oral Di 8:229-240
2. Jones AV, Craig GT, Speight PM et al (2008) The range and demographics of salivary gland tumours diagnosed in a UK population. Oral Oncol 44:407-417 (Pubitemid 351380985)
3. Gooden E, Witterick IJ, Hacker D et al (2002) Parotid gland tumours in 255 consecutive patients: Mount Sinai Hospital's quality assurance review. J Otolaryngol 31:351-354 (Pubitemid 36286371)
4. Mendenhall WM, Riggs CEJ, Cassisi NJ (2005) Cancer: Principles and Practice of Oncology. Journal/Treatment of head and neck cancers 662-732
5. Arshad AR (1998) Parotid swellings: report of 110 consecutive cases. Med J Malaysia 53:417-422
6. Daley T and Darling M (2003) Nonsquamous cell malignant tumours of the oral cavity: an overview. J Can Dent Assoc 69:577-582
7. Loyola AM, de Araujo VC, de Sousa SO et al (1995) Minor salivary gland tumours. A retrospective study of 164 cases in a Brazilian population. Eur J Cancer B Oral Oncol 31B:197-201
8. Theriault C and Fitzpatrick PJ (1986) Malignant parotid tumors. Prognostic factors and optimum treatment. Am J Clin Oncol 9:510-516 (Pubitemid 17205981)
9. Licitra L, Grandi C, Prott FJ, et al. (2003) Major and minor salivary glands tumours. Crit Rev Oncol Hematol 45:215-225 (Pubitemid 36216314)
10. Witt RL (2004) Major salivary gland cancer. Surg Oncol Clin N Am 13:113-127 (Pubitemid 38328497)
11. Atula T, Grenman R, Klemi P et al (1998) Human papillomavirus, Epstein-Barr virus, human herpesvirus 8 and human cytomegalovirus involvement in salivary gland tumours. Oral Oncol 34:391-395 (Pubitemid 28440303)
12. Karja V, Syrjanen K and Syrjanen S (1997) No Epstein Barr and cytomegalovirus DNA found in salivary gland tumours. ORL J Otorhinolaryngol Relat Spec 59:97-99 (Pubitemid 27197364)
13. Sun EC, Curtis R, Melbye M et al (1999) Salivary gland cancer in the United States. Cancer Epidemiol Biomarkers Prev 8:1095-1100 (Pubitemid 30004907)
14. Brandwein MS, Ferlito A, Bradley PJ et al (2002) Diagnosis and classification of salivary neoplasms: pathologic challenges and relevance to clinical outcomes. Acta Otolaryngol 122:758-764 (Pubitemid 35398889)
15. Seifert G and Donath K (1996) Hybrid tumours of salivary glands. Definition and classification of five rare cases. Eur J Cancer B Oral Oncol 32B:251-259
16. Guzzo M, Andreola S, Sirizzotti G et al (2002) Mucoepidermoid carcinoma of the salivary glands: clinicopathologic review of 108 patients treated at the National Cancer Institute of Milan. Ann Surg Oncol 9:688-695 (Pubitemid 34857987)
17. Goode RK, Auclair PL and Ellis GL (1998) Mucoepidermoid carcinoma of the major salivary glands: clinical and histopathologic analysis of 234 cases with evaluation of grading criteria. Cancer 82:1217-1224 (Pubitemid 28155381)
18. Brandwein MS, Ivanov K, Wallace DI et al (2001) Mucoepidermoid carcinoma: a clinicopathologic study of 80 patients with special reference to histological grading. Am J Surg Pathol 25:835-845 (Pubitemid 32594976)
19. Spiro RH, Huvos AG and Strong EW (1982) Adenocarcinoma of salivary origin. Clinicopathologic study of 204 patients. Am J Surg 144:423-431 (Pubitemid 12037514)
20. Davies L and Welch HG (2006) Epidemiology of head and neck cancer in the United States. Otolaryngol Head Neck Surg 135:451-457
21. Batsakis JG, Regezi JA, Luna MA et al. (1989) Histogenesis of salivary gland neoplasms: a postulate with prognostic implications. J Laryngol Otol 103:939-944 (Pubitemid 19251855)
22. Kokemueller H, Eckardt A, Brachvogel P et al (2004) Adenoid cystic carcinoma of the head and neck- a 20 years experience. Int Int J Oral Maxillofac Surg 33:25-31 (Pubitemid 38035489)
23. Waldron CA, el-Mofty SK and Gnepp DR (1988) Tumors of the intraoral minor salivary glands: a demographic and histologic study of 426 cases. Oral Surg Oral Med Oral Pathol 66:323-333
24. Buchner A, Merrell PW and Carpenter WM (2007) Relative frequency of intra-oral minor salivary gland tumors: a study of 380 cases from northern California and comparison to reports from other parts of the world. J Oral Pathol Med 36:207-214 (Pubitemid 46495986)
25. Wahlberg P, Anderson H, Biorklund Aet al (2002) Carcinoma of the parotid and submandibular glands -a study of survival in 2465 patients. Oral Oncol 38:706-713 (Pubitemid 34880110)
26. Yih WY, Kratochvil FJ and Stewart JC (2005) Intraoral minor salivary gland neoplasms: review of 213 cases. J Oral Maxillofac Surg 63:805-810 (Pubitemid 40745295)
27. Conley J and Arena S (1963) Parotid Gland as a Focus of Metastasis. Arch Surg 87:757-764
28. Nichols RD, Pinnock LA and Szymanowski RT (1980) Metastases to parotid nodes. Laryngoscope 90:1324-1328 (Pubitemid 10089943)
29. Greene F (2002) AJCC Cancer Staging Manual
30. Vander Poorten VL, Balm AJ, Hilgers FJ et al (1999) Prognostic factors for long term results of the treatment of patients with malignant submandibular gland tumors. Cancer 85:2255-2264 (Pubitemid 29215567)
31. Gunderson LL and Tepper JE (2007) Clinical Radiation Oncology. 2nd ed. Elsevier Saunders
32. Armstrong JG, Harrison LB, Spiro RH et al (1990) Malignant tumors of major salivary gland origin. A matched-pair analysis of the role of combined surgery and postoperative radiotherapy. Arch Otolaryngol Head Neck Surg 116:290-293
33. Frankenthaler RA, Luna MA, Lee SS, et al (1991) Prognostic variables in parotid gland cancer. Arch Otolaryngol Head Neck Surg 117:1251-1256
34. North CA, Lee DJ, Piantadosi S, et al (1990) Carcinoma of the major salivary glands treated by surgery or surgery plus postoperative radiotherapy. Int J Radiat Oncol Biol Phys 18:1319-1326 (Pubitemid 20234142)
35. Spiro IJ, Wang CC and Montgomery WW (1993) Carcinoma of the parotid gland. Analysis of treatment results and patterns of failure after combined surgery and radiation therapy. Cancer 71:2699-2705
36. Brackrock S, Krull A, Roser K et al (2005) Neutron therapy, prognostic factors and dedifferentiation of adenoid cystic carcinomas (ACC) of salivary glands. Anticancer Res 25:1321-1326 (Pubitemid 40546809)
37. Day TA, Deveikis J, Gillespie MB et al (2004) Salivary gland neoplasms. Curr Treat Options Oncol 5:11-26 (Pubitemid 38899297)
38. Perez CA, Brady LW and Halperin EC (2004) Principles and Practice of Radiation Oncology
39. Ben-David MA, Diamante M, Radawski JD et al (2007) Lack of osteoradionecrosis of the mandible after intensity-modulated radiotherapy for head and neck cancer: likely contributions of both dental care and improved dose distributions. Int J Radiat Oncol Biol Phys 68:396-402 (Pubitemid 46694162)
40. Laurie SA and Licitra L (2006) Systemic therapy in the palliative management of advanced salivary gland cancers. J Clin Oncol 24:2673-2678 (Pubitemid 46622089)
41. Licitra L, Marchini S, Spinazze S et al (1991) Cisplatin in advanced salivary gland carcinoma. A phase II study of 25 patients. Cancer 68:1874-1877
42. Airoldi M, Brando V, Giordano C et al (1994) Chemotherapy for recurrent salivary gland malignancies: experience of the ENT Department of Turin University. ORL J Otorhinolaryngol Relat Spec 56:105-111 (Pubitemid 24050556)
43. Dimery IW, Legha SS, Shirinian M et al (1990) Fluorouracil, doxorubicin, cyclophosphamide, and cisplatin combination chemotherapy in advanced or recurrent salivary gland carcinoma. J Clin Oncol 8:1056-1062 (Pubitemid 20200194)
44. Hill ME, Constenla DO, A'Hern RP et al (1997) Cisplatin and 5-fluorouracil for symptom control in advanced salivary adenoid cystic carcinoma. Oral Oncol 33:275-278
45. Dreyfuss AI, Clark JR, Fallon BG et al (1987) Cyclophosphamide, doxorubicin, and cisplatin combination chemotherapy for advanced carcinomas of salivary gland origin. Cancer 60:2869-2872 (Pubitemid 18005856)
46. Alberts DS, Manning MR, Coulthard SW et al (1981) Adriamycin/cis- platinum/cyclophosphamide combination chemotherapy for advanced carcinoma of the parotid gland. Cancer 47:645-648
47. Venook AP, Tseng AJr., Meyers FJ et al (1987) Cisplatin, doxorubicin, and 5-fluorouracil chemotherapy for salivary gland malignancies: a pilot study of the Northern California Oncology Group. J Clin Oncol 5:951-955 (Pubitemid 17120002)
48. Airoldi M, Pedani F, Brando V et al. (1989) Cisplatin, epirubicin and 5-fluorouracil combination chemotherapy for recurrent carcinoma of the salivary gland. Tumori 75:252-256 (Pubitemid 19192950)
49. de Haan LD, De Mulder PH, Vermorken JB et al (1992) Cisplatin-based chemotherapy in advanced adenoid cystic carcinoma of the head and neck. Head Neck 14:273-277
50. Triozzi PL, Brantley A, Fisher S et al (1987) 5-Fluorouracil, cyclophosphamide, and vincristine for adenoid cystic carcinoma of the head and neck. Cancer 59:887-890 (Pubitemid 17024639)
51. Airoldi M, Pedani F, Succo G et al (2001) Phase II randomized trial comparing vinorelbine versus vinorelbine plus cisplatin in patients with recurrent salivary gland malignancies. Cancer 91:541-547 (Pubitemid 32105699)
52. Gedlicka C, Schull B, Formanek M et al (2002) Mitoxantrone and cisplatin in recurrent and/or metastatic salivary gland malignancies. Anticancer Drugs 13:491-495 (Pubitemid 34621053)
53. Airoldi M, Fornari G, Pedani F et al. (2000) Paclitaxel and carboplatin for recurrent salivary gland malignancies. Anticancer Res 20:3781-3783 (Pubitemid 32002275)
54. Gilbert J, Li Y, Pinto HA et al (2006) Phase II trial of taxol in salivary gland malignancies (E1394): a trial of the Eastern Cooperative Oncology Group. /Head Neck 28:197-204 (Pubitemid 43269885)
55. Harari PM and Huang SM (2000) Modulation of molecular targets to enhance radiation. Clin Cancer Res 6:323-325 (Pubitemid 30111446)
56. Agulnik M, Cohen EE, Cohen RB et al (2006) A phase II study of lapatinib in recurrent or metastatic EGFR and/or ErbB2 expressing adenoid cystic (ACC) and non-ACC malignant tumors of the salivary glands (MSGT). J Clin Oncol 2006 ASCO Annual Meeting Proceedings 24:5566
57. Chen CH, Li BY, Wan JT et al (2001) Expression of epidermal growth factor in salivary adenoid cystic carcinoma. Proc Natl Sci Counc Repub China B 25:90-96
58. Etges A, Pinto DS, Jr., Kowalski LP et al (2003) Salivary duct carcinoma: immunohistochemical profile of an aggressive salivary gland tumour. J Clin Pathol 56:914-918 (Pubitemid 37533233)
59. Fan CY, Melhem MF, Hosal AS et al (2001) Expression of androgen receptor, epidermal growth factor receptor, and transforming growth factor alpha in salivary duct carcinoma. Arch Otolaryngol Head Neck Surg 127:1075-1079
60. Martinez-Barba E, Cortes-Guardiola JA, Minguela-Puras A et al (1997) Salivary duct carcinoma: clinicopathological and immunohistochemical studies. J Craniomaxillofac Surg 25:328-334 (Pubitemid 28051218)
61. Vered M, Braunstein E and Buchner A (2002) Immunohistochemical study of epidermal growth factor receptor in adenoid cystic carcinoma of salivary gland origin.Head Neck 24:632-636 (Pubitemid 34734357)
62. Yamada K, Iwai K, Okada Y et al (1989) Immunohistochemical expression of epidermal growth factor receptor in salivary gland tumours. Virchows Arch A Pathol Anat Histopathol 415:523-531 (Pubitemid 19251331)
63. Rubin Grandis J, Melhem MF, Gooding WE et al (1998) Levels of TGF-alpha and EGFR protein in head and neck squamous cell carcinoma and patient survival. J Natl Cancer Inst 90:824-832 (Pubitemid 28280548)
64. Barnes L, Rao U, Contis L et al (1994) Salivary duct carcinoma. Part II. Immunohistochemical evaluation of 13 cases for estrogen and progesterone receptors, cathepsin D, and c-erbB-2 protein. Oral Surg Oral Med Oral Pathol 78:74-80
65. Cho KJ, Kim JY, Lee SS et al (1997) Mucoepidermoid carcinoma of the salivary gland-a clinico-pathologic and immunohistochemical study for c-erbB-2 oncoprotein. J Korean Med Sci 12:499-504
66. Cho KJ, Lee SS and Lee YS (1999) Proliferating cell nuclear antigen and c-erbB-2 oncoprotein expression in adenoid cystic carcinomas of the salivary glands. Head Neck 21:414-419
67. Dori S, Vered M, David R et al (2002) HER2/neu expression in adenoid cystic carcinoma of salivary gland origin: an immunohistochemical study. J Oral Pathol Med 31:463-467
68. Felix A, El-Naggar AK, Press MF et al (1996) Prognostic significance of biomarkers (c-erbB-2, p53, proliferating cell nuclear antigen, and DNA content) in salivary duct carcinoma. Hum Pathol 27:561-566 (Pubitemid 26187279)
69. Glisson B, Colevas AD, Haddad R et al (2004) HER2 expression in salivary gland carcinomas: dependence on histological subtype. Clin Cancer Res 10:944-946 (Pubitemid 38198894)
70. Karja V, Syrjanen S, Kataja V et al (1994) c-erbB-2 oncogene expression in salivary gland tumours. ORL J Otorhinolaryngol Relat Spec 56:206-212 (Pubitemid 24183197)
71. Kernohan NM, Blessing K, King G et al (1991) Expression of c-erbB-2 oncoprotein in salivary gland tumours: an immunohistochemical study. J Pathol 163:77-80
72. Press MF, Pike MC, Hung G et al (1994) Amplification and overexpression of HER-2/neu in carcinomas of the salivary gland: correlation with poor prognosis. Cancer Res 54:5675-5682 (Pubitemid 24346266)
73. Shintani S, Funayama T, Yoshihama Y et al (1995) Expression of c-erbB family gene products in adenoid cystic carcinoma of salivary glands: an immunohistochemical study. Anticancer Res 15:2623-2626 (Pubitemid 26095072)
74. Skalova A, Starek, Kucerova Vet al (2001) Salivary duct carcinoma -a highly aggressive salivary gland tumor with HER-2/neu oncoprotein overexpression. Pathol Res Pract 197:621-626 (Pubitemid 32834402)
75. Skalova A, Starek I, Vanecek T et al (2003) Expression of HER-2/neu gene and protein in salivary duct carcinomas of parotid gland as revealed by fluorescence in situ hybridization and immunohistochemistry. Histopathology 42:348-356 (Pubitemid 36459812)
76. Sugano S, Mukai K, Tsuda H et al (1992) Immunohistochemical study of c-erbB-2 oncoprotein overexpression in human major salivary gland carcinoma: an indicator of aggressiveness. Laryngoscope 102:923-927
77. Giannoni C, el-Naggar AK, Ordonez NG et al (1995) c-erbB-2/neu oncogene and Ki-67 analysis in the assessment of palatal salivary gland neoplasms. Otolaryngol Head Neck Surg 112:391-398
78. Nagler RM, Kerner H, Ben-Eliezer S et al (2003) Prognostic role of apoptotic, Bcl-2, c-erbB-2 and p53 tumor markers in salivary gland malignancies. Oncology 64:389-398 (Pubitemid 36682953)
79. Stenman G, Sandros J, Nordkvist A et al (1991) Expression of the ERBB2 protein in benign and malignant salivary gland tumors. Genes Chromosomes Cancer 3:128-135
80. Haddad R, Colevas AD, Krane JF et al (2003) Herceptin in patients with advanced or metastatic salivary gland carcinomas. A phase II study. Oral Oncol 39:724-727 (Pubitemid 36930120)
81. Agulnik M, Cohen EW, Cohen RB et al (2007) Phase II study of lapatinib in recurrent or metastatic epidermal growth factor receptor and/or erbB2 expressing adenoid cystic carcinoma and non adenoid cystic carcinoma malignant tumors of the salivary glands. J Clin Oncol 25:3978-3984 (Pubitemid 47477277)
82. Penner CR, Folpe AL and Budnick SD (2002) C-kit expression distinguishes salivary gland adenoid cystic carcinoma from polymorphous low-grade adenocarcinoma. Mod Pathol 15:687-691 (Pubitemid 34787302)
83. Holst VA, Marshall CE, Moskaluk CA et al(1999) KIT protein expression and analysis of c-kit gene mutation in adenoid cystic carcinoma. Mod Pathol 12:956-960 (Pubitemid 29485269)
84. Jeng YM, Lin CY and Hsu HC (2000) Expression of the c-kit protein is associated with certain subtypes of salivary gland carcinoma. Cancer Lett 154:107-111
85. Hotte SJ, Winquist EW, Lamont Eet al (2005) Imatinib mesylate in patients with adenoid cystic cancers of the salivary glands expressing c-kit: a Princess Margaret Hospital phase II consortium study. J Clin Oncol 23:585-590 (Pubitemid 46224236)
86. Lim JJ, Kang S, Lee MR et al (2003) Expression of vascular endothelial growth factor in salivary gland carcinomas and its relation to p53, Ki-67 and prognosis. J Oral Pathol Med 32:552-561 (Pubitemid 37175008)
87. Doi R, Kuratate I, Okamoto E et al (1999) Expression of p53 oncoprotein increases intratumoral microvessel formation in human salivary gland carcinomas. J Oral Pathol Med 28:259-263 (Pubitemid 29298249)
88. Ellis GL and Auclair PL (Armed Forces Institute of Pathology, 1996) Tumors of the salivary glands. Atlas of Tumor Pathology, third series, Fascicle 11